BEGIN:VCALENDAR
PRODID:-//github.com/ical-org/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:STANDARD
DTSTART:20241103T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZNAME:EST
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250309T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZNAME:EDT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:SPEAKER : Joseph G. Ibrahim\, PhD\, Alumni Distinguished Profe
 ssor\, Department of Biostatistics\, University of North Carolina at Chap
 el Hill TITLE : “Cure Rate Joint Model for Time-to-Event Data and Longitu
 dinal Tumor Burden with Potential Change Points ” ABSTRACT: In non-small 
 cell lung cancer (NSCLC) clinical trials\, tumor burden (TB) is a key lon
 gitudinal biomarker for assessing treatment effects. Typically\, standard
 -of-care (SOC) therapies and some novel interventions initially decrease 
 TB\; however\, many patients subsequently experience an increase—indicati
 ng disease progression—while others show a continuous decline. In patient
 s with an eventual TB increase\, the change point marks the onset of prog
 ression and must occur before the time of the event. To capture these dis
 tinct dynamics\, we propose a novel joint model that integrates time-to-e
 vent and longitudinal TB data\, classifying patients into a change-point 
 group or a stable group. For the changepoint group\, our approach flexibl
 y estimates an individualized change point by leveraging time-to-event in
 formation. We use a Monte Carlo Expectation-Maximization (MCEM) algorithm
  for efficient parameter estimation. Simulation studies demonstrate that 
 our model outperforms traditional approaches by accurately capturing dive
 rse disease progression patterns and handling censoring complexities\, le
 ading to robust marginal TB outcome estimates. When applied to a Phase 3 
 NSCLC trial comparing cemiplimab monotherapy to SOC\, the treatment group
  shows prolonged TB reduction and consistently lower TB over time\, highl
 ighting the clinical utility of our approach. The implementation code is 
 publicly available on https://github.com/quyixiang/JoCuR . YSPH values in
 clusion and access for all participants. If you have questions about acce
 ssibility or would like to request an accommodation\, please contact Char
 mila Fernandes at Charmila.fernandes@yale.edu . We will try to provide ac
 commodations requested by September 15\, 2026.\n\nSpeaker:\nJoseph G. Ibr
 ahim\, PhD\n\nAdmission:\nFree\n\nFood:\nRefreshments at 3:45 PM\n\nDetai
 ls URL:\nhttps://medicine.yale.edu/event/ysph-biostatistics-seminar-09-21
 -26/\n
DTEND;TZID=America/New_York:20260921T170000
DTSTAMP:20260928T083328Z
DTSTART;TZID=America/New_York:20260921T160000
GEO:41.303666;-72.932218
LOCATION:Yale School of Public Health (LEPH)\, 115\, 60 College Street\, N
 ew Haven\, CT\, United States
SEQUENCE:0
STATUS:Confirmed
SUMMARY:YSPH Biostatistics Seminar: "Cure Rate Joint Model for Time-to-Eve
 nt Data and Longitudinal Tumor Burden with Potential Change Points"
UID:a48577e2-ad50-4671-b872-206ac4261eab
END:VEVENT
END:VCALENDAR